0 [5.7-15.1] ng/ ml compared with obese patients 18.8 [12.9-24.2] ng/ml (p<0.0000001) independently of liver complications. In alcoholic patients 40.2% had a steatohepatitis and 20.6% a bridging fibrosis. The levels of 25-OH vitamin D were decreased in patients with steatohepatitis or

with bridging fibrosis but its low level was independently associated only with steatohepatitis (6.5 [4.5-8.0] vs 12.0 [6.6-18.4] ng/ml, p=0.000003). In morbidly obese patients, 20.6% had a steatohepatitis, 28.9% a “moderate” fibrosis (F≥2 according to the NASH CRNSS) and 4.3% a bridging fibrosis. The 25-OH vitamin D level decreased with “moderate” fibrosis (15.9 [11.1-23.5] vs 19.6 [13.7-24.7] MAPK Inhibitor Library in vivo ng/ml, P=0.02) but not with bridging fibrosis and not with NASH. Stages of fibrosis were independently associated with steatohepatitis in alcoholic and obese patients, respectively, but not with a vitamin D deficiency. Conclusion: Alcoholic patients were frequently deficient in 25-OH vitamin D. This was highly more frequent compared

to morbidly obese patients. In alcoholic patients, low levels of 25-OH vitamin D were associated with the bridging fibrosis and independently associated with the presence of alcoholic steatohepatitis. The role of vitamin D in the evolution of fibrosis could be indirect through the severity of Selleck HM781-36B the inflammation. In morbidly obese patients, these associations were not found. Vitamin D supplementation in alcoholic patients should be tested in clinical trials to determine if it is possible to prevent or reduce Rucaparib research buy the severity of liver histology

and mortality. Disclosures: The following people have nothing to disclose: Clémence M. Canivet, Rodolphe Anty, Stephanie Patouraux, Antonio Iannelli, Patricia Panaia-Ferrari, Imed Ben Amor, Anne-Sophie Schneck, Marie-Christine M. Saint-Paul, Jean Gugenheim, Philippe Gual, Albert Tran Background and Aims: Several metabolic disorders, such as type 2 diabetes (T2DM), obesity, and hepatic steatosis, are associated with liver cirrhosis (LC) and development of hepato-cellular carcinoma (HCC). New genetic loci that contribute to the development of T2DM have been identified by genome-wide association studies. The aim of this study was to examine the association between T2DM susceptibility loci and liver disease progression in Japanese patients with T2DM.